FindTrial
Sign In

On the discordance and clinical significance of ER, PR, HER2, Ki-67 and molecular type status between primary breast cancer and synchronous axillary lymph nodes metastases

On the discordance and clinical significance of ER, PR, HER2, Ki-67 and molecular type status between primary breast cancer and synchronous axillary lymph nodes metastases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15007247
Enrollment
Unknown
Registered
2015-10-08
Start date
2015-10-21
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Molecular type change group:non
Molecular type no change group:non

Sponsors

The First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Post operative patients with unilateral breast cancer who underwent axillary lymph node metastasis in the same period, and received no chemotherapy, radiotherapy or endocrine therapy before surgery, As well as clinical and pathological data were complete; 2. Age of 18~75 years old.

Exclusion criteria

Exclusion criteria: Breast cancer patients with non- synchronous axillary lymph nodes metastases, Breast cancer patients with neoadjuvant chemotherapy, Bilateral Breast cancer patients, Occult breast cancer Patients.

Design outcomes

Primary

MeasureTime frame
Estrogen receptor(ER);Progesterone receptor(PR);Ki-67;Human epidermal growth factor receptor 2(Her-2);—

Countries

China

Contacts

Public ContactKong Ling-quan
huihuikp@163.com+86 13101380893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026